IDDI in the Media.
Read the articles related to our know-how and expertise in clinical research and how we optimize the design and conduct of clinical trials.
IDDI in Contract Pharma
Insight on the pharma and biopharma trends impacting CROs, Outsourcing in today’s market, and advances in clinical research. READ IDDI ARTICLE PUBLISHED IN CONTRACT PHARMA ! Kristin Brooks, Contract Pharma 04.27.20 Serge Bodart of IDDI provides insight on the pharma […]
Surrogate endpoints create potential, require statistical validation
Transforming statistical data into a surrogate endpoint can enable comprehension of trial results sooner than usual, but few make the cut after formal validation, says drug development expert and DIA panelist. READ ARTICLE HERE Interview of Dr. Marc Buyse, ScD, […]
Using disease free survival as a primary endpoint in early breast cancer
IDDI in collaboration with Roche have identified why using disease-free survival as a primary endpoint in early breast cancer is the way forward IDDI’s findings suggest that it is appropriate to use disease-free survival (DFS) as a surrogate for overall […]
IDDI: coup de pouce à la médecine personnalisée
IDDI: coup de pouce à la médecine personnalisée L’entreprise de Louvain-la-Neuve développe une méthode statistique innovante, qui pourrait bousculer les essais cliniques. CHRISTOPHE DE CAEVEL Trends Tendances P20 Feb.21, 2019 Vous trouvez que les projets de recherche conduisent trop rarement […]
Personalized Medicine: Getting More Out of Clinical Trials
February 15, 2019
IDDI in Contract Pharma Magazine IDDI, BMS Consortium aims to establish that the GPC statistical method can complement the design, analysis and interpretation of clinical trial results; Kristin Brooks, Contract Pharma 02.15.19 Results of randomized clinical trials can be somewhat limited. […]